항체 위탁개발생산기관 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 공급원별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Antibody CDMO Market Growth & Trends:

The global antibody CDMO market is expected to reach USD 58.40 billion by 2030, expanding at a CAGR of 14.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.

Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.

Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.

The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.

Antibody CDMO Market Report Highlights:

• Monoclonal antibodies segment accounted for the largest share of 67.6% in 2022.The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics
• Based on the source, the mammalian segment accounted for the largest share of 58.5% in 2022. High shares of the segment are majorly due to increasing rates of outsourcing witnessed across mammalian antibody therapeutics, as the cost of production of such antibodies is significantly high. Hence, CDMOs offer these manufacturing services at a comparatively lower cost than in-house production rates, thus supporting its large segment share in the market
• The immune-mediated disorders segment is anticipated to register the fastest CAGR of 14.6% during the forecast period. This is due to the growing rate of clinical trials targeted at discovering novel antibodies in the treatment of immune-mediated disorders
• Biopharmaceutical companies are anticipated to register the fastest CAGR of 14.3% from 2023 to 2030, owing increasing number of biopharmaceutical companies focusing on producing novel antibody therapeutics, thus supporting its lucrative growth during the forecast period
• Asia Pacific is anticipated to witness the highest CAGR of 14.2% during the forecast time frame. High growth is majorly due to Asian countries such as India and China, where the cost of production is comparatively lower than in Western economies, thus attracting a larger customer base across the region and thereby supporting the region's growth

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Product
  • 1.1.3. Source
  • 1.1.4. Therapeutic Area
  • 1.1.5. End Use
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective-1
  • 1.4.2. Objective-2
  • 1.4.3. Objective-3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Antibody CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Antibody CDMO Services
    • 3.2.1.2. Rising Incidence of Cancer
    • 3.2.1.3. High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing Contributing to Demand For Outsourcing Services
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality Issues While Outsourcing
    • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
• 3.3. Antibody CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis
  • 3.3.4. Clinical Trial Volume Analysis for Antibody Research, (2022)
  • 3.3.5. Regulatory Landscape:
    • 3.3.5.1. U.S.
    • 3.3.5.2. Europe
    • 3.3.5.3. Asia Pacific
    • 3.3.5.4. Rest of the World

Chapter 4. Antibody CDMO Market: Product Estimates & Trend Analysis

• 4.1. Antibody CDMO Market, By Product: Segment Dashboard
• 4.2. Antibody CDMO Market, By Product: Movement Analysis
• 4.3. Antibody CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
  • 4.3.1. Monoclonal Antibodies
    • 4.3.1.1. Monoclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
  • 4.3.2. Polyclonal Antibodies
    • 4.3.2.1. Polyclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Others Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 5. Antibody CDMO Market: Source Estimates & Trend Analysis

• 5.1. Antibody CDMO Market, By Source: Segment Dashboard
• 5.2. Antibody CDMO Market, By Source: Movement Analysis
• 5.3. Antibody CDMO Market Estimates & Forecasts, By Source, 2018 - 2030
  • 5.3.1. Mammalian
    • 5.3.1.1. Mammalian Antibody CDMO Market, 2018 to 2030 (USD Million)
  • 5.3.2. Microbial
    • 5.3.2.1. Microbial Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 6. Antibody CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Antibody CDMO Market, By Therapeutic Area: Segment Dashboard
• 6.2. Antibody CDMO Market, By Therapeutic Area: Movement Analysis
• 6.3. Antibody CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
  • 6.3.1. Oncology
    • 6.3.1.1. Oncology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.2. Neurology
    • 6.3.2.1. Neurology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.3. Cardiology
    • 6.3.3.1. Cardiology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.4. Infectious Diseases
    • 6.3.4.1. Infectious Diseases Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.5. Immune-mediated Disorders
    • 6.3.5.1. Immune-mediated Disorders Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.6. Others
    • 6.3.6.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Antibody CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Antibody CDMO Market, By End Use: Segment Dashboard
• 7.2. Antibody CDMO Market, By End Use: Movement Analysis
• 7.3. Antibody CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 7.3.1. Biopharmaceutical Companies
    • 7.3.1.1. Biopharmaceutical Companies Antibody CDMO Market 2018 to 2030 (USD Million)
  • 7.3.2. Research Laboratories
    • 7.3.2.1. Research Laboratories Antibody CDMO Market 2018 to 2030 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 8. Antibody CDMO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2022 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Competitive Scenario
    • 8.5.1.3. Regulatory Framework
    • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 8.5.2. Germany
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 8.5.3. France
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 8.5.4. Italy
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 8.5.5. Spain
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 8.5.6. Denmark
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 8.5.8. Norway
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Competitive Scenario
    • 8.6.1.3. Regulatory Framework
    • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 8.6.2. India
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 8.6.4. South Korea
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 8.6.6. Thailand
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key Country Dynamics
    • 8.7.1.2. Competitive Scenario
    • 8.7.1.3. Regulatory Framework
    • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 8.7.2. Mexico
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key Country Dynamics
    • 8.8.1.2. Competitive Scenario
    • 8.8.1.3. Regulatory Framework
    • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 8.8.3. UAE
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 8.8.4. Kuwait
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Innovators
  • 9.1.2. Market Leaders
  • 9.1.3. Emerging Players
  • 9.1.4. Company Market Share Analysis, 2022
• 9.2. Company Profiles
  • 9.2.1. Lonza
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Service Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Catalent, Inc
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Service Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Samsung Biologics
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Service Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. WuXi Biologics
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Service Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. AGC Biologics
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Service Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. AbbVie Inc.
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Service Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Boehringer Ingelheim International GmbH
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Service Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Charles River Laboratories
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Service Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. FUJIFILM Holdings Corporation
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Service Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. mAbxience
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Service Benchmarking
    • 9.2.10.4. Strategic Initiatives